-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, 2:30-3:30 p.m. ET.
-
"EMTALA: The Essential Guide to Compliance" from Thomson American Health Consultants, publisher of ED Legal Letter and Hospital Risk Management, explains how the changes to EMTALA will affect emergency departments and off-campus clinics. In-depth articles, at-a-glance tables, and Q-and-A discussions of real-life situations are presented, and key differences between the old EMTALA and the new changes are succinctly explained.
-
Historically, ED Legal Letter has evaluated the mistakes of physicians after the fact. The diagnosis has been missed, the case has been litigated and decided. The benefit of hindsight provides an essential learning and risk management opportunity for the reader. This months issue will evaluate the thinking and behavior of physicians that lead to errors in diagnosis. An analysis of the cognitive errors in the ED by physicians will provide reflection on future premature or inaccurate diagnosis in the ED. This issue will allow physicians to recognize that certain types of thinking and behavior can be harmful to the patient. Acknowledging these faults will reduce bad outcomes and prevent future litigation.
-
-
-
Staphylococcus aureus is a versatile enemy. It is spreading in the community, as well as in the hospital, with increasing resistance to antibiotics. Its armamentarium now includes not only resistance to methicillin and vancomycin but also means of spread and pathogenic mechanisms we clearly need to know more aboutand soon.
-
-
The final version of the recently proposed changes to the Emergency Medical Treatment and Labor Act (EMTALA) takes effect Nov. 10.
-
Extended hormonal contraception is drawing dramatic attention due to the desire of many women to reduce or eliminate the number of withdrawal bleeds associated with current birth control methods.
-
Gemifloxacin is effective as standard treatment for the treatment of ABECB and CAP; however, in limited trials it does not seem to be more efficacious or safe than other standard drug therapy for these indications.